EGFR and head and neck squamous cell carcinoma: So far, only cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, and, more recently, nivolumab and pembrolizumab, PD-1 inhibitors, have been approved for the treatment of HNSCC.